NEW YORK (
CHANGE IN RATINGS, EPS
upgraded to buy at TheStreet ratings.
(AMD - Get Report)
upgraded at Wells from Market Perform to Outperform. Company is guiding toward better near-term growth.
target raised at Goldman to $53. Positive earnings call commentary. Maintain Buy rating.
price target raised at Goldman to $28. Costs saves a modest plus, but expect muted PM-USA profit in 2012. Neutral rating.
downgraded at UBS from Buy to Neutral. $20 price target. Major concerns about ability to execute and two SEC investigations.
estimates raised at Goldman through 2011 following through this quarter's upside. Maintain $47 price target and Buy rating.
Bristol Myers Squibb
target raised at UBS. BMY price target increased to $32. Launches still key, growth continues. Neutral rating.
(BG - Get Report)
estimates, target reduced at Credit Suisse. BG estimates were cut through 2012. Agribusiness profits will likely be lower than expected. Outperform rating and new $72 price target.
(CAM - Get Report)
estimates, target reduced at Credit Suisse. Shares of CAM now seen reaching $71. Estimates also cut, as the company is seeing slower growth in North America. Outperform rating.
estimates, target boosted at Credit Suisse. Shares of CERN now seen reaching $67. Higher sales are driving margin growth. Neutral rating.
(KO - Get Report)
rated new Buy at Deutsche. KO was initiated with a Buy rating. $75 price target. Growth potential remains highest in the emerging markets.
(CYH - Get Report)
downgraded at Wells from Outperform to Market Perform. Admission rates have been hurt by Tenet's allegations.
downgraded at Jefferies from Hold to Underperform. $51 price target. Competitors are more attractive ways to play this sector.
numbers raised at Credit Suisse. Shares of DECK now seen reaching $122. Estimates also increased, as Ugg continues to drive growth. Outperform rating.
(DOW - Get Report)
estimates, target cut at Credit Suisse. DOW estimates were cut through 2012. Company is seeing lower demand across the board. Outperform rating and new $40 price target.
Dow Chemical estimates lowered at UBS through 2012. Third quarter was in line, but rough patch is coming. Maintain $38 price target and Buy rating.